about
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysisNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 montCenter-Within-Trial Versus Trial-Level Evaluation of Surrogate EndpointsAchieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology GroupsPreliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trialsComparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerChallenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.Adaptive adjustment of the randomization ratio using historical control data.Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouseRandom effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses.Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas.Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial.A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.A three-outcome design for phase II clinical trials.Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741Validation of novel imaging methodologies for use as cancer clinical trial end-pointsIndividual patient data analysis to assess modifications to the RECIST criteria.Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancerCurrent issues in oncology drug development, with a focus on Phase II trialsRevised TN categorization for colon cancer based on national survival outcomes data.Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setCommensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR statusRandomized phase II clinical trials.KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.Bayesian variable selection with joint modeling of categorical and survival outcomes: an application to individualizing chemotherapy treatment in advanced colorectal cancerAssociation study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
P50
Q26860637-E30BE319-6DE6-4317-AC15-72B79CDA3AD8Q28131668-B1514F36-08D5-4428-9336-92CEC68CC887Q28681140-67FFAC0C-7901-4041-9290-63DF5A61D362Q30370596-66C82F8F-99B1-4AC6-B59D-D5BCEA0152E1Q30413920-CD38E9E9-5CEA-4461-B829-52C277BAFF6FQ30413922-CF67EE07-352D-4877-8DAE-A812779CBCC9Q30422446-F1617571-72A1-4FF6-B254-53E15F0A79C5Q30424507-7A464D1E-6047-45C0-AADE-5482FB7A20AAQ30586297-3D052D78-EAB4-4FAD-8A25-C3190250B153Q30629562-753583AD-FA61-463C-9BEC-71654578C8C5Q30754691-69967135-0DE7-46D6-A8BF-541FD38F452AQ30983032-6A51A22D-1B25-4418-A171-40D8268AC634Q31014850-826009EB-D9E9-4FA9-92AF-3DC8885F19B4Q31026840-9F6B524E-A2CC-4A27-B28C-7396325AE76EQ31081979-7FF42049-CC6B-4F6C-9F8A-8C8C5D76F666Q31130903-2E1BCA1B-74ED-4201-A338-E1C2FA8C9B5DQ31131055-050E9580-45D1-4F54-8424-7742A89BE514Q31155033-0DAEB028-EDC6-4926-8891-64BE93226FC0Q33181907-04E19E79-47B6-42D7-83A9-F3DF6251927DQ33347089-21783535-8981-4BFB-BBB5-137327F9D752Q33347128-C1A52BEC-74D5-4825-BBF6-3438D43F54C3Q33372496-8EA83B5F-BEC1-4290-BB76-1DA28F388D20Q33383727-995B7F5D-BAA6-43FB-B4F1-B1BB365B7247Q33394106-48AB5715-3B52-4E52-9EF5-ACAEA4AB4C19Q33394490-E1A644FC-BA1E-4938-A806-51A9AEA74272Q33397671-D7880E66-A1D8-4B37-B2D8-1BB15B11A5CDQ33414068-3A046A77-1BB9-492D-8A71-11D82525AECDQ33433456-697522B7-B3CE-424E-AE5A-36583C3838A7Q33516922-AD768397-D267-4A6C-AD44-43398CC2B8ADQ33518321-72E421A9-3F14-4A42-B99C-5C3842151464Q33554378-D3B3005D-41D5-4CF2-8EB5-A13BF958692AQ33579892-8FF46822-AE53-42D9-B58F-84DBACA084A6Q33586020-A2A88E4B-E7BB-4D70-948F-2F1CCE5976E7Q33605194-E4CB7394-EB57-42B8-AC01-9E3B109595C5Q33620091-0F48A75B-97F5-41B9-80F0-3D620AE00914Q33624082-724EE8AA-3E22-475B-942E-31D09163E6ABQ33693309-ED31E5FE-7D93-4C61-B573-EC8751E3C496Q33791812-86B6824E-979F-42D1-9641-36CFE53E92C2Q33852448-4B27C847-7B57-44E9-8E2F-22FEB148D2D7Q33855053-82EA0934-A924-49F1-878D-3323B12F4744
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniel J Sargent
@es
Daniel J Sargent
@fr
Daniel J Sargent
@sl
Daniel J. Sargent
@en
Daniel J. Sargent
@nl
type
label
Daniel J Sargent
@es
Daniel J Sargent
@fr
Daniel J Sargent
@sl
Daniel J. Sargent
@en
Daniel J. Sargent
@nl
prefLabel
Daniel J Sargent
@es
Daniel J Sargent
@fr
Daniel J Sargent
@sl
Daniel J. Sargent
@en
Daniel J. Sargent
@nl
P106
P108
P1153
7005878661
P21
P31
P496
0000-0002-2684-4741